Browse Title Index


 
Issue Title
 
Vol 3, No 4 (2002) Osteoporosi: la malattia e il suo costo sanitario Abstract   PDF
Gianpaolo Zara, Carlo Della Pepa, Lorenzo Pradelli, Mario Eandi
 
Vol 12, No 3S (2011) Palivizumab e virus respiratorio sinciziale: una panoramica Abstract   PDF
Paolo Manzoni
 
Vol 12, No 3S (2011) Palivizumab nella profilassi del virus respiratorio sinciziale: analisi di impatto sul budget del SSN italiano Abstract   PDF
Daniela Roggeri
 
Vol 8, No 2 (2007) Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects Abstract   PDF
Lorenzo Pradelli, Mario Eandi
 
Vol 4, No 1 (2003) Parecoxib nel trattamento del dolore postoperatorio: considerazioni farmacoeconomiche Abstract   PDF
Lorenzo Pradelli, Mario Eandi
 
Vol 5, No 4 (2004) Parecoxib nel trattamento del dolore post-operatorio: considerazioni farmacoeconomiche Abstract   PDF
Federica Mathis, Lorenzo Pradelli, Mario Eandi
 
Vol 5, No 1 (2004) Parnaparin: confronto con le altre eparine a basso peso molecolare Abstract   PDF
Lorenzo Pradelli, Mario Eandi
 
Vol 6, No 3 (2005) Parnaparin: confronto con le altre eparine a basso peso molecolare Abstract   PDF
Lorenzo Pradelli
 
Vol 9, No 1 (2008) Parnaparin: review of the literature Abstract   PDF
Lorenzo Pradelli
 
Vol 16, No 2 (2015) Patient reported outcomes to support drug development decision making Details   HTML   PDF
Annabel Nixon, Diane Wild, Willie Muehlhausen
 
Vol 8, No 1 (2007) Pay-back direct to Regions: a new possibility for companies Details   PDF
Orietta Zaniolo
 
Vol 9, No 4 (2008) Peg-interferon plus ribavirin in chronic hepatitis C: cost-efficacy and pharmacoutilization in clinical practice Abstract   PDF
Luisa Cavalletto, Elisabetta Bernardinello, Giulio Diodati, Enzo Raise, Angelo Gatta, Liliana Chemello
 
Vol 13, No 4 (2012) Perceval Sutureless valves in isolated and concomitant AVR procedures: an economic model shows overall decrease of costs for isolated or combined operations Abstract   HTML   PDF
Lorenzo Pradelli, Orietta Zaniolo
 
Vol 1, No 1 (2000) Percorsi diagnostico-terapeutici nella gestione dei pazienti affetti da polmonite acquisita in comunità Abstract   PDF
Mario Eandi
 
Vol 19, No 1 (2018) Personalized medicine: biomarkers and companion diagnostics Abstract   HTML   PDF
Renato Bernardini, Giovanni Gancitano, Angela Balice, Rosaria Di Mauro, Giuseppina Cantarella, Matteo Dionisi
 
Vol 7, No 3 (2006) Pharmacoeconomic analysis of biological treatments for psoriatic arthritis Abstract   PDF
Mario Eandi, Carlo Salvarani
 
Vol 8, No 2 (2007) Pharmacoeconomic analysis of long term use of darbepoetin-α in treating chronic nephropathy-induced anemia in dialysed patients Abstract   PDF
Nicola Giotta, Ercole Biamino, Mario Eandi
 
Vol 9, No 3 (2008) Pharmacoeconomic analysis of valsartan for the treatment of chronic congestive heart failure in Italy Abstract   PDF
Sergio Iannazzo, Lorenzo Pradelli, Orietta Zaniolo
 
Vol 12, No 3 (2011) Pharmacoeconomic aspects of poor adherence to treatment in multiple sclerosis management Abstract   HTML   PDF
Mario Eandi
 
Vol 15, No 4 (2014) Pharmacoeconomic aspects related to the 13-valent pneumococcal conjugate vaccine: preliminary analysis of the data from the ASL of Viterbo Abstract   HTML   PDF
Silvia Dari, Flavia Verginelli, Silvia Aquilani
 
Vol 12, No 1 (2011) Pharmacoeconomic comparison of ziprasidone with other atypical oral antipsychotic agents in schizophrenia Abstract   PDF
Andrea Fagiolini, Alice Matone, Claudio Gaz, Simona Panunzi, Andrea De Gaetano
 
Vol 10, No 2 (2009) Pharmacoeconomic evaluation of influenza vaccination programs in elderly in Italy Abstract   PDF
Sergio Iannazzo, Viola Sacchi
 
Vol 11, No 1 (2010) Pharmacoeconomic evaluation of the costs incurred by the ASP Messina for home therapy with liquid oxygen Abstract   PDF
Salvatore Coppolino
 
Vol 7, No 1 (2006) Pharmacoeconomic profile of vitamin D3: in the prevention of osteoporosis Abstract   PDF
Orietta Zaniolo
 
Vol 7, No 4 (2006) Pharmacoutilization of anti-inflammatory and gastroprotective drugs in patients with osteoarthritis: comparison between COXIBs and conventional NSAIDs by using administrative records Abstract   PDF
Luca Degli Esposti, Mirko Di Martino, Guido Didoni, Chiara Veronesi, Stefania Saragoni, Stefano Buda
 
Vol 13, No 2S (2012) Piemonte Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Piemonte Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 15, No 1 (2014) Precision medicine: key applications and considerations for commercial success & market access Details   HTML   PDF
Morten Søgaard, Indranil Bagchi, Mikael Dolsten
 
Vol 6, No 3 (2005) Pregabalin versus gabapentin nel trattamento dei pazienti con neuropatia periferica: adattamento di un modello internazionale per la valutazione di costo/efficacia e costo/utilità alla realtà nazionale Abstract   PDF
Paolo Marchettini, Lisa Da Deppo, Lorenzo Pradelli
 
Vol 11, No 1 (2010) Prevalence in the Italian regions of pain in patients with diabetic peripheral neuropathy (NDP) and the current costs of drug treatment for principals with specific indication Abstract   PDF
Luca Guidi
 
Vol 14, No 2S (2013) Prevention of VTE in orthopedic surgery patients Abstract   HTML   PDF
Federico Spandonaro, Rossella Letizia Mancusi, Lorenzo Terranova, Diana Giannarelli, Paolo Grossi, Davide Imberti, Emilio Mazza
 
Vol 6, No 3 (2005) Prevenzione e terapia precoce del diabete mellito di tipo II: aspetti farmacoeconomici Abstract   PDF
Lorenzo Pradelli
 
Vol 13, No 2 (2012) Pricing and reimbursement of innovative pharmaceuticals in France and the new healthcare reform Abstract   HTML   PDF
Alexander Natz, Marie-Geneviève Campion
 
Vol 16, No 2 (2015) Process reengineering: the experience of electrophisiology center of the Local Health Unit of Viterbo Abstract   HTML   PDF
Mario Malavasi, Silvia Dari
 
Vol 4, No 4 (2003) Profilo clinico ed economico di oxatomide Abstract   PDF
Lorenzo Pradelli, Mario Eandi
 
Vol 6, No 3 (2005) Profilo farmacologico clinico e farmacoeconomico di un gel oftalmico a base di carbomero 974P e PVA (Siccafluid®) nella terapia della cheratocongiuntivite secca Abstract   PDF
Lorenzo Pradelli, Letizia Vacchini
 
Vol 5, No 2 (2004) Profilo terapeutico e farmacoeconomico di linezolid Abstract   PDF
Mario Eandi
 
Vol 12, No 3 (2011) Prophylaxis against febrile neutropenia with pegfilgrastim in Italy: a budget impact analysis Abstract   HTML   PDF
Giovanni Rosti, Maria Lebboroni, Ario Cerchiari, Pablo Katz
 
Vol 9, No 1 (2008) PROVE-IT trial: economic analysis Abstract   PDF
Simona de Portu, Sabato Montella, Simona Cammarota, Anna Citarella, Lorenzo G. Mantovani
 
Vol 13, No 2S (2012) Puglia Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Puglia Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 7, No 3 (2006) Rational and irrational factors in the dynamics of pharmaceutical expenditure and in the drug price negotiation Details   PDF
Mario Eandi
 
Vol 6, No 2 (2005) Razionalizzare la spesa ospedaliera: Day-Hospital, ADI, Hospice Abstract   PDF
Mario Eandi
 
Vol 21, No 1 (2020) Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region Abstract   HTML   PDF
Monica Bocchia, Alberto Bosi, Enrico Capochiani, Stefania Ciolli, Romano Danesi, Sara Galimberti, Alessandro Gozzetti, Sabrina Moretti, Ubaldo Occhini, Mario Petrini
 
Vol 15, No 2 (2014) Real‑life cost and cost‑effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48‑month survey Abstract   HTML   PDF
Massimiliano Povero, Lorenzo Pradelli, Paola Turco, Roberto Walter Dal Negro
 
Vol 18, No 1 (2017) Recently approved recombinant factor VIII (rFVIII) for the replacement treatment in patients with hemophilia A in Italy Details   HTML   PDF
Daniela Paola Roggeri, Ezio Zanon, Alessandro Roggeri
 
Vol 11, No 1 (2010) Regional control of pharmaceutical expenditure in the DL May 31, 2010 No 78 Details   PDF
Mario Eandi
 
Vol 13, No 2S (2012) Regione “Test” Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 12, No 3 (2011) Report OsMed related to the first nine months of 2011 Details   HTML   PDF
Ombretta Bandi
 
Vol 15, No 2 (2014) Research gaps and Health Technology Assessment Details   HTML   PDF
Leela Barham
 
Vol 7, No 2 (2006) Resistenza all’uso degli ipoglicemizzanti orali nel trattamento del diabete tipo 2: uno studio multicentrico Abstract   PDF
Gianluca Falcitelli, Giuseppe Armentano, Corrado Pugliesi, Patrizio Tatti, Antonio Cimino
 
Vol 14, No 2 (2013) Results of reference pricing and reimbursement discount rate schemes of Turkey Abstract   HTML   PDF
Guvenc Kockaya, Kagan Atikeler, Esin Tuna, Pelin Kılıc, Pelin Tanyeri, Nurcan Umman, İsmail Mert Vural, Omer Altun, Akif Akbulat, Guven Artiran, Ercan Simsek, Hakkı Gursoz, Saim Kerman
 
Vol 5, No 1 (2004) Rettifica al lavoro: considerazione cliniche ed economiche nel trattamento del cancro della prostata: analisi costo/efficacia di bicalutamide vs. flutamide in combinazione con LHRH Details   PDF
Sebastiano Maurizio Castorina
 
Vol 11, No 1 (2010) Revisiting the role of a service-Day Hospital in infectious diseases, based on the natural history of HIV infection in the era of potent antiretroviral combination therapy Abstract   PDF
Roberto Manfredi
 
Vol 6, No 1 (2005) Rifaximina nel trattamento della malattia diverticolare: potenziale terapeutico ed economico Abstract   PDF
Orietta Zaniolo, Mario Eandi
 
Vol 14, No 1 (2013) Role of pharmacoeconomics in developing countries Details   HTML   PDF
Amani Mori, Paul Gavaza, Bjarne Robberstad
 
Vol 9, No 2 (2008) Rotigotine patches (Neupro) in early Parkinson’s disease Abstract   PDF
Viola Sacchi
 
Vol 13, No 2S (2012) Sardegna Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Sardegna Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 9, No 2 (2008) Sartans: differences, similitudes and costs Abstract   PDF
Orietta Zaniolo, Sergio Iannazzo
 
Vol 13, No 2S (2012) Sicilia Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Sicilia Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 17, No 1S (2016) Simulating the development and progression of Chronic Kidney Disease and osteoporosis in people living with HIV Abstract   HTML   PDF
Silvano Adami, Paolo Maggi, Vincenzo Montinaro, Massimiliano Povero, Lorenzo Pradelli, Rita Bellagamba, Paolo Bonfanti, Antonio Di Biagio, Stefano Rusconi, Francesco Maria Di Campli, Giuseppe Forastieri, Michele Mancini
 
Vol 8, No 1 (2007) Simvastatin: between clinics and health economics Abstract   PDF
Francesco Vittorio Costa, Orietta Zaniolo
 
Vol 9, No 1 (2008) Solifenacin in overactive bladder syndrome: pharmacoeconomic analysis Abstract   PDF
Sergio Iannazzo, Lorenzo Pradelli
 
Vol 1, No 2 (2000) Stato di salute degli italiani e prospettive di spesa sanitaria e farmaceutica Abstract   PDF
Mario Eandi
 
Vol 3, No 4 (2002) Storia naturale dell’infiammazione allergica Abstract   PDF
Maria Angela Tosca, Giorgio Ciprandi
 
Vol 10, No 3 (2009) Sugammadex in antagonism of neuromuscular block in anesthesia: a clinical and economic profile Abstract   PDF
Viola Sacchi, Sergio Iannazzo, Francesco Giunta
 
Vol 6, No 2 (2005) Sulodexide: implicazioni cliniche ed economiche Abstract   PDF
Orietta Zaniolo, Mario Eandi
 
Vol 4, No 3 (2003) Sviluppo e implementazione di un modello farmacoeconomico per valutare la costo efficacia di un ACE-inibitore nella prevenzione del rischio cardiovascolare Abstract   PDF
Sergio Iannazzo, Lorenzo Pradelli, Mario Eandi
 
Vol 7, No 1 (2006) Taxane therapy in the adjuvant treatment of breast cancer in Italy: economic evaluation Abstract   PDF
Simona Ravera, Lorenzo G. Mantovani
 
Vol 9, No 4 (2008) Telbivudine (Sebivo) in patients with hepatitis B virus (HBV) chronic infection Abstract   PDF
Viola Sacchi
 
Vol 7, No 2 (2006) Telithromycin (Ketek®)in lower respiratory tract infections: economic aspects Abstract   PDF
Carlo Lazzaro
 
Vol 6, No 1 (2005) Terapia del dolore: nuove norme e aspetti pratici per l’uso degli analgesici Abstract   PDF
Lorenzo Pradelli
 
Vol 6, No 1 (2005) Terlipressina: profilo farmacologico clinico, terapeutico e farmacoeconomico nel trattamento delle varici esofagee Abstract   PDF
Lorenzo Pradelli
 
Vol 16, No 4 (2015) The aging of Europe. The unexplored potential Details   HTML   PDF
Mihajlo Jakovljevic
 
Vol 7, No 2 (2006) The breakthrough of public pharmaceutical expenditure in 2005 Details   PDF   PDF
Mario Eandi
 
Vol 7, No 3 (2006) The clinical and economic value of lovastatin in the primary prevention of cardiovascular disease Abstract   PDF
Lorenzo Pradelli, Orietta Zaniolo
 
Vol 10, No 2 (2009) The clinical and economic value of the dipeptide alanyl-glutamine in total parenteral nutrition of critically ill patients treated in intensive care units in Italy Abstract   PDF
Maurizio Muscaritoli, Lorenzo Pradelli, Orietta Zaniolo, Sergio Iannazzo, Mario Eandi
 
Vol 18, No 1 (2017) The cost of a combination Anti-Retroviral Therapy (cART) optimization pathway as maintenance therapy in HIV-1 infected patients Abstract   HTML   PDF
Roberto Ravasio, Fabio Rigo, Emanuela Lattuada, Ercole Concia, Massimiliano Lanzafame
 
Vol 13, No 1 (2012) The cost-effectiveness of prevention: is an ounce of prevention worth a pound of cure? Details   HTML   PDF
Steven Simoens
 
Vol 9, No 1 (2008) The discovery of “sale amarissimo antifebbrile” (“bitter febrifugal saline”) by Bartolommeo Rigatelli, i.e. the origins of pharmacoeconomics Abstract   PDF
Piero Marson, Giampiero Pasero
 
Vol 21, No 1 (2020) The Economic Burden of Different Multiple Sclerosis Courses: Analysis from Italian Administrative and Clinical Databases Abstract   HTML
Paolo Angelo Cortesi, Paolo Cozzolino, Ruggero Capra, Giancarlo Cesana, Lorenzo Giovanni Mantovani
 
Vol 15, No 1S (2014) The economic impact associated with cerebrovascular events related to non-valvular atrial fibrillation (NVAF) in Italy: the role of apixaban Details   HTML   PDF
Lorenzo Pradelli, Mario Calandriello, Roberto Di Virgilio, Marco Bellone, Marco Tubaro
 
Vol 13, No 2 (2012) The effect of obesity upon Health Related Quality of Life (HRQoL): A comparison of the AQoL-8D and SF-36 instruments Abstract   HTML   PDF
Munir Ahmed Khan, Jeff Richardson, Paul O'Brien
 
Vol 12, No 1 (2011) The health and social costs of chronic kidney disease in Italy Abstract   PDF
Americo Cicchetti, Matteo Ruggeri, Paola Codella, Alessandro Ridolfi
 
Vol 7, No 4 (2006) The health-economic models: practical aspects and management of uncertainty Abstract   PDF
Sergio Iannazzo
 
Vol 23, No 1 (2022) The Importance of Real-World Evidence in Understanding Influenza Vaccine Effectiveness Details   HTML   PDF
Pietro Ferrara, Lorenzo Giovanni Mantovani
 
Vol 24, No 1 (2023) The Importance of the Pharmacoeconomic Analyses in Drug Negotiation. A Farewell Editorial Details   HTML   PDF
Mario Eandi
 
Vol 20, No 1 (2019) The Management of Psoriatic Arthritis in Italy: Organizational Impact Analysis of Optimized Pathways Abstract   HTML   PDF
Umberto Restelli, Carlo Selmi, Valeria Pacelli, Davide Croce, Antonio Costanzo
 
Vol 10, No 4 (2009) The pharmaceutical expenditure in Italy in 2009: toward regional federalism Details   PDF
Mario Eandi
 
Vol 13, No 2 (2012) The public and patients should have their say in HTA Details   HTML   PDF
Leela Barham
 
Vol 16, No 4 (2015) The regulatory and Health Technology processes in Europe and drug market access. The case of cystic fibrosis Abstract   HTML   PDF
Mayra Latorre Martinez, Pedro Serrano, Antonio Sarria Santamera
 
Vol 15, No 4 (2014) The trend of pharmaceutical expenditure in Italy: from the report OsMed 2013 to the monitoring 2014 Details   HTML   PDF
Mario Eandi
 
Vol 10, No 4 (2009) The use of corticosteroids in patients with chronic obstructive pulmonary disease: epidemiological and economic aspects Abstract   PDF
Pablo M. Katz, Valeria Pegoraro
 
Vol 14, No 1S (2013) The use of dexmedetomidine in intensive care sedation Abstract   HTML   PDF
Massimo Antonelli, Giorgio Conti, Andrea Belisari, Lucia S. D'Angiolella, Lorenzo Mantovani, Sabato Montella, Patrizio Piacentini, Marco Ranieri
 
Vol 14, No 3 (2013) The utility of a model-based cost-effectiveness analysis of degarelix versus leuprolide in the therapy of hormone-dependent advanced prostate cancer Abstract   HTML   PDF
Massimo Perachino, Mario Eandi
 
Vol 20, No 1 (2019) The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis Abstract   HTML   PDF
Paolo Angelo Cortesi, Damiano Paolicelli, Marco Capobianco, Paolo Cozzolino, Lorenzo Giovanni Mantovani
 
Vol 10, No 2 (2009) Theory and practice of the Health Technology Assessment in countries with a predominant public health service Details   PDF
Mario Eandi
 
Vol 7, No 4 (2006) Tigecycline: a review of the literature Abstract   PDF
Mario Venditti, Maria Elena Pompeo, Flavia Fabi
 
301 - 400 of 477 Items << < 1 2 3 4 5 > >>